Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe things are great, maybe things are bad, but we don’t know because they tell us nothing… It’s hard to be optimistic at this point
What a bunch of frauds…complete clown show 🤡
“If a ZIVO conference call happens in the forest, and nobody is around to hear it, does it make a sound?” 🤔
Mike,
Are they taking calls from shareholders at this meeting?… I haven’t seen any notification about this… I wonder if they actually have the guts to take calls from some of us… I certainly have a few choice things to say if given the chance…
Mike,
I’ve mistakenly traded very little over the years…Treated this one as a buy/hold option, particularly after the late 2018 info about the molecule discovery, and was also hopeful that something would happen first with Mastitis, and then then the company would have some cash, and away we would go…A series of conversations I’ve had over the years, along with other a few other things, with those in the poultry industry in NOCAL and southern Oregon where I resided at the time, made me understand the industry’s DESPERATE need for a natural product like the Algae produced by ZIVO…Mastitis, Coccidiosis,Inflammation ,Bird flu etc, are VERY SERIOUS issues for all involved at every level of the poultry business world, and have been for years…my thinking was the Proalgazyme was going to become a legit natural option by 2022/23…SILLY ME!!…antibiotic treatments, are simply small Band-Aids on large wounds for the industry, and that will not change anytime soon… So I will just have to sit, hope and wait, but at this point, I’m expecting nothing, and that’s what it looks like we’re gonna get from ZIVO.
At this point, I agree with you Tony and think we will be lucky to get $10/share, which for those of us who’ve held the stock for to long like myself, would be awful.
Got it, thx
That makes sense, thank you
Thank you for explaining that… let’s say something were to happen, wouldn’t it make sense to do another reverse split, not in the direction of the previous two, to put more shares out on the market?
Weazelboy,
I’ve NEVER understood ZIVO, and almost everything they’ve done during my 17+ years of owning shares of this wretched company… I’m also not very knowledgeable when it comes to understanding the implications, good or bad, for ZIVO concerning the info you just posted…hoping you could explain further…
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
DOWNLOAD AS PDF FEB 07, 2024
Reduction in intestinal damage enables poultry farms to optimize feed utilization
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product’s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics.
ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO’s product across the broiler production value chain.
ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore.
ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO’s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.
“We are confident that ZIVO’s product will offer poultry producers a novel tool to accelerate the development of the immune system in young birds, thereby mitigating the impact of coccidial infection, reducing intestinal tissue damage and fostering overall animal health and well-being to maximize profitability. As we further analyze the results of our most recent 42-day challenge study, we are finding that our coccidiosis treatment candidate exhibits the potential to revolutionize the industry by achieving significantly improved poultry outcomes at cost parity or better. We believe these findings will facilitate and expand dialogues with potential partners in the agriculture and animal health industries,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike wish to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
Mike,
Last project update from Z 9/23/22… now would be the perfect time for the company to give some details about what occurred during the most recent 42 day testing with the chickens… One of the many questions I have, is, how was the algae administered to the chickens?… Was it a 100% natural application using nothing but the dried algae added to the chicken’s food, and if so, how much was needed to achieve the desired results, and how will the supply demands be handled moving forward?… And if the algae was not administered, naturally, is their some type of pharmaceutical application being developed with the rarely-never mentioned anymore molecule the world needs to know about?… So many more questions, but that’s it for now…
You may be right, but this is ZIVO…in my 17+ years as a shareholder, to say they do things differently would be an understatement…trust me when I tell you to expect the unexpected…
Mike,
Assuming the chicken study started October 30, 2023, same day as the press release, 42 days from that point is December 12, 2023…The Christmas and New Year’s holiday began shortly after, and I’m guessing minimal work was completed until after January 2, 2024…IMO, that data is gonna take 4-6 weeks MINIMUM to analyze, meaning I’m not expecting the results to be announced until late January at the earliest, and more realistically, early to mid February…and per usual, EVERYTHING is a guess with this company!
WTH??🤷🤣
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
DOWNLOAD AS PDF SEP 19, 2023
All test groups demonstrated statistically significant benefit in broiler health under simulated commercial conditions
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups.
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billion (Re-calculating the Cost of Coccidiosis in Chickens; Blake, D., Knox, J., et al.). Products for treating coccidiosis are mostly antibiotic or ionophore-based, and no commercially significant new technology has been introduced in the past 60 years.
The disease challenge used in this trial closely replicated conditions often seen in commercial broiler production facilities experiencing a coccidiosis outbreak, including commercially relevant incidence and severity of intestinal lesions, mortality, and other disease related measures. Birds treated with ZIVO’s product candidate demonstrated statistically significant improvements across all measures of broiler health examined. Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds.
“These results are very encouraging as they demonstrate our product’s potential to mitigate the effects of coccidiosis while acting through a highly desirable non-antibiotic mechanism of action. We now plan to launch the final phase of the product candidate’s validation, which involves a 42-day confirmatory study performed under broiler industry-relevant conditions such as those used in the present study. We expect to have results from this confirmatory study near the end of 2023,” said John Payne, CEO and Chairman of ZIVO Bioscience.
The results of this recent study of multiple product batches, including product used in the inconclusive study earlier this year, align with those of over 20 prior successful trials that closely replicated disease levels observed in commercial production settings. Thus, validating that ZIVO’s product candidate maintains stability over an extended period, with no decrease in its effectiveness. As a result, ZIVO remains confident that its novel product candidate for broiler chickens presents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry.
"ZIVO’s biotech business is a significant driver of value creation, and we are prioritizing our coccidiosis candidate and working with the USDA’s Center for Veterinary Biologics on the regulatory path toward licensure of a product for the treatment and prevention of this disease. This strategy best optimizes value by achieving sustainable revenue in the shortest timeframe possible. In addition to the poultry market, our research suggests there are numerous additional health benefits and disease treatments to be derived from our proprietary algal culture for livestock, companion animals, and humans. We intend to pursue those additional opportunities, as well, should resources become available,” added Mr. Payne.
Mike,
I’m certainly not celebrating, but it’s a start…Also, nice to see GA is actually gonna increase the algae production…Hopefully we get some news on the chickens soon too…
Well, maybe you were correct about the U-turn Gwinner… sometimes it’s great to be wrong!
Gwinner,
Your optimism is admirable, but the only U-turn this group of Bozo’s is making is northbound into southbound rush hour traffic on the same California freeways I take to work everyday!
Mike,
Thank you for your input…Some of this is new to me, and your explanation of the latest events was helpful…Now, how about some frickn’ revenue!!!!
The Q1 posted yesterday is not pretty
It’s certainly not because they respond to email inquiries…sent my fifth question to them yesterday and still no reply to any of them
IMO it’s wiped out…and to think otherwise is just plain foolish at this point
I’m in a more helpless spot than you… selling any shares now for me, would be a loss… I have held my position, even added it to it some post 80-1 split, not listening to my gut that said sell at certain points… once John Payne took over, I figured I could least break, even after 17 long and grueling years of holding, holding and holding by spring 2023… until yesterday, shareholders had been given no reason to believe that revenue was something the company could achieve at some point in the first half this year… Now it’s difficult to tell if anything will even happen in 2023 and beyond… To say Yesterdays PR was a gut punch, would be putting it mildly… At this point, I’m done following the stock, and will just wait for the next email sometime later this year telling me things have gone from bad to worse for this wretched excuse of a “company”…
And it doesn’t like that that will ever change
Just tried myself and got the exact response
Should we really be surprised?…Adios ZIVO Bioscience…
They haven’t responded to any of my 3 emails , and I’ve been told by another shareholder I know that they did not answer either of her 2 phone calls…clowns!!
I was just thinking about ZIVO 2022, and there is no doubt the highlight of the year for me was that incredibly informative early November conference call mentioned in the10/24 PR…Everything anyone would need to know about this company, was covered and I just wish I’d had all that info prior to buying the shares I did just a little over 17 years ago…
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
DOWNLOAD AS PDF OCT 24, 2022
ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products
Conference call to be held in early November
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC (“ZIVOLife”), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company’s proprietary algae biomass.
“Today’s news is a transformative development for ZIVO Bioscience because the structure of the Company’s operations will allows for a new era of innovation, financial leverage and focus. Executing on the strategy discussed in my recent letter to shareholders, this strategic direction advances the unique opportunity we hold in being able to manufacture at commercial scale a consistent, quality product that is attractive to potential customers and partners alike,” said John Payne, President and Chief Executive Officer of ZIVO Bioscience.
Under the new corporate structure, ZIVO Bioscience will grant ZIVOLife an exclusive worldwide limited license to the Company’s intellectual property related to proprietary algal cultures, for the production and supply of whole algae biomass products from ZIVO Bioscience’s proprietary algal cultures for limited application for human consumption and skincare, excluding all animal and pharmaceutical (human and animal) applications. ZIVOLife will, in turn, enter into long-term strategic sales, marketing and distribution agreements.
Upon the signing of a definitive license agreement, ZIVO Bioscience will be eligible to receive royalty payments from ZIVOLife for the licensed use of the Company’s proprietary algal cultures and farming technology used in production, and will grant ZIVOLife rights to the ZIVO name. The new structure allows ZIVOLife to raise capital from third parties to advance and expand its business. The Company believes these transactions should create substantial value for ZIVO Bioscience stakeholders by accelerating the path to revenue, sharpening its strategic focus on biotechnology products and expanding growth opportunities. To the extent ZIVOLife attracts additional third-party investment in the future, ZIVO Bioscience’s interest in the operations of ZIVOLife may be diluted.
“ZIVO Bioscience has made important progress to date, yet there is much more to do that is best accomplished under this new structure. As the Company’s Biotechnology and Agricultural business segments continue to grow, so do their differences and the need for separate structures and operations. The creation of ZIVOLife continues this evolution by enabling each segment to pursue distinct growth strategies while allowing ZIVO Bioscience shareholders to participate in the success of both companies,” added Mr. Payne.
With separate business structures, ZIVO Bioscience and ZIVOLife will be better positioned to:
Focus on their core strategic priorities, with distinct capital structures and financial targets that best support their markets, opportunities and success;
Execute with increased agility and operational flexibility, deploying capital and resources in a manner consistent with those strategic priorities;
Optimize each business for profitable growth;
Attract and retain talent that’s best suited for distinct businesses and geographies; and
Provide a clear investment thesis and transparency to attract investors that are most appropriate for each company.
In addition, ZIVOLife announces the appointment of ZWorldwide Inc. (“ZWorldwide”) as the first, exclusive authorized global reseller and distributor of algae products produced by ZIVOLife. ZWorldwide is a Florida-based company created for the specific purpose of distributing ZIVOLife algae products for human consumption in raw powdered form. Due to its nutrition profile, algae-based products are intended to be used as a food or food ingredient and are not to be used in the treatment of ailments, disease or other health issues.
With responsibility for production and supply, ZIVOLife holds the right to sublicense algal culture and farming technology to contracted growers, but will maintain control of global inventory to be re-sold and distributed through its distribution agreements such as the one with ZWorldwide. This structure enables ZIVOLife to pursue global market opportunities by commercializing products in geographies that are conducive to the proprietary algae technology.
Conference Call
ZIVO Bioscience management will host a conference call in early November to discuss this new corporate structure and answer questions. Details regarding the date, time and how to participate will be provided in a separate news release.
At least we now know nothing is happening anytime soon cuz we heard it from the CEO… I also think it’s safe to say that the previous management team left behind an even bigger internal mess for Mr. Payne and friends to clean up than any of us may have realized…Oh well, hope everyone on this site has a great holiday season and a happy new year, and I’ll be checking back sometime in mid-2023 for another update about nothing…
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
To My Fellow Shareholders,
Having served as a member of the Board of Directors of ZIVO Bioscience since 2013 and as Chairman since 2019, I’ve been integrally involved in setting ZIVO’s strategy and evaluating the potential of a range of valuable products derived from our proprietary algal culture. Now serving as President and CEO, I’m focusing our Company to deliver commercial results quickly and in areas of highest value. Through establishing partnerships and scaling our manufacturing capacity, ZIVO is undergoing a transformation aimed at maximizing the value of our product portfolio for our customers, partners, and shareholders.
Since I assumed day-to-day leadership at the start of this year, my colleagues and I have left no stone unturned in reviewing all avenues to best reshape ZIVO to maximize the value of our products and our intellectual property. We have worked diligently to build the necessary infrastructure, and I believe that 2023 will showcase the results of our efforts.
I’m proud to share that our redeveloped strategy is materializing nicely and that we are in a stronger position than ever before to achieve meaningful revenue and recognition for the value of our assets. Our strategy remains two-pronged and is focused on driving significant value inflection through targeted development of our biotech business and delivering near-term revenue through our agtech business. Regardless of the end market, we will maximize value through partnerships and by commercializing the unique capabilities of products derived from our proprietary algal culture.
Through this letter I’d like to provide an overview of why others find our product candidates to be so attractive. I will then share my vision for ZIVO to maximize commercial potential, our long-term strategy to achieve that vision, the steps we are taking now, and the near-term goals our shareholders can look forward to us achieving.
Corporate Direction
ZIVO’s past efforts have clearly demonstrated that our proprietary algal culture and materials derived therefrom show promise in benefiting both animal and human health, primarily through inflammation-modulating and immune-boosting properties. Prior to this calendar year, ZIVO’s approach to extracting value from our proprietary algal culture was to simultaneously evaluate many potential applications in parallel. This strategy spread both our personnel and monetary resources across multiple opportunities, resulting in slow progress down various paths. Although we believe that each of the paths being evaluated may yield success in the future, we did not have the resources for this strategy to be successful in an acceptable timeframe.
Overall, our efforts were centered around two value-creating initiatives; the first being the identification of bioactive extracts or novel bioactive molecules from our proprietary algal culture that are effective in treating various diseases, and second, the utilization of our proprietary algal culture in its whole form as a food product to leverage its nutritional value. In the first quarter of this year, we reformulated our biotech and agtech businesses around these two concepts. We reviewed the market potential (scale and profit) and the technical and business risks associated with each of the opportunities we had been working on and developed a focused strategy for each business.
Biotech Business Strategy
ZIVO’s go-to-market biotech strategy is to partner with established animal health companies and create value through licensing or other commercial arrangements, while accelerating final product development and mitigating market introduction risk.
Review of isolated active materials derived from our proprietary algal culture and their potential treatment applications led us to identify a product candidate for treating coccidiosis in broiler chickens as the best option for most rapidly generating significant revenue because coccidiosis is a global poultry industry issue costing chicken farmers between $8-13 billion annually, and because the clinical testing cycle for chickens is shorter than for other species. Most of the global animal health companies have products for the coccidiosis market; however, they are mostly antibiotic- or ionophore-based with essentially no new technology having been introduced in the last 60 years.
The successful commercial launch of our coccidiosis product for broiler chickens has the potential to disrupt the broiler industry, attract multiple potential partners and enable expansion into other animal species and disease applications.
Coccidiosis Product Candidate
In numerous prior studies, ZIVO has demonstrated multiple benefits, including:
Minimized or eliminated the negative effects of coccidiosis on the digestive health in broiler chickens by numerous measures of gut health and overall well-being
Delivered efficacy at a cost per bird on par with conventional antibiotics and chemicals currently used in treating coccidiosis
Reduced the incidence of Campylobacter, Salmonella, E. coli, and Clostridium perfringens, all significant sources of food-borne illness, in the digestive tract of broilers in the absence of antibiotics or other antimicrobial compounds
Reduced mortality
The predominant treatment for coccidiosis in the poultry industry, in-feed anticoccidial drugs target the Eimeria parasite directly and require constant use over the lifespan of the animal for efficacy and can over time result in the development of resistant Eimeria strains. Other treatment strategies, such as vaccines, require several weeks for immunity to manifest, which can significantly impact growth potential. Often, several treatment products are used in combination, increasing costs in an industry already facing heavy inflationary pressures. As a result, the poultry industry is actively searching for a novel solution.
ZIVO’s treatment alternative represents an innovative new product class that primes and strengthens the immune system through multiple complementary immune pathways to afford a rapid and robust response to the effects of disease-causing pathogens without the adverse effects associated with traditional antimicrobial drugs and chemicals.
To execute on our refocused biotech strategy, we recently engaged with a leading global animal health company. Our in-depth discussions with this company have led to an interest in our product candidate as a complement to their existing poultry feed additive product portfolio. ZIVO has signed a material transfer and evaluation agreement to allow our potential partner to run validation testing on our lead product candidate. Discussions remain ongoing and there can be no assurance they will result in a definitive agreement, yet we expect to have more clarity in the first quarter of 2023 following the completion of their internal and third-party validation studies.
Our potential partner has begun a four-month comprehensive validation study of our product candidate, including a 42-day coccidiosis trial in broiler chickens. Results from the validation study are expected in the first quarter of 2023. We remain confident this validation study will again confirm the desired efficacy profile given ZIVO’s numerous prior successful studies. Pending positive results from the ongoing trial, our goal will be to secure a development and license agreement in the first half of next year.
USDA Regulatory Strategy
ZIVO’s approach for developing our coccidiosis product candidates as feed additives enables us to generate products that boost the immune response and reduce the effects of disease, while maintaining a single regulatory relationship, which is with the U.S. Department of Agriculture (USDA).
We recently announced receipt of a letter from the USDA’s Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing our immune-modulating biologic for treating coccidiosis in broiler chickens. This important jurisdictional announcement de-risks our regulatory path and opens the door to further discussions with the CVB on the final product development plan, regulatory strategy, and data requirements for licensure.
Agtech Business Strategy
For the agtech side of our business, we have thoughtfully developed our proprietary algal culture to be commercially viable as a nutritional product. The powdered form contains approximately 45% protein, is an excellent source of other essential nutrients, and is nearly completely odorless and tasteless unlike other algal products, characteristics that favor rapid adoption and consumer acceptance. As we reviewed our agtech business early this year, we were very satisfied with the nature of the product; however, we identified gaps in customer acquisition and in scale-up technology allowing us to grow our proprietary algae in quantities to sufficiently meet the potential demand. We have therefore focused our agtech strategy on developing a cost effective, commercial-scale growing technology.
In 2021, we began funding a development agreement with Grupo Alimenta, a well-established Peruvian agriculture company. Through ZIVO’s direction and technology, a site in Ica, Peru has been successful in consistently producing high-quality ZIVO proprietary algae. The achievement of a consistent commercial-grade product is attractive to potential customers and partners alike, but our focus is now on scaling up for commercial production. The Alimenta-ZIVO team has been working toward building commercial-scale algae ponds using a ZIVO proprietary design, and we are in the middle of a project to grow our algae in a penultimate scale pond. Once we are successful at this scale, we plan, in the first quarter of 2023, to invest in full commercial-scale ponds and product processing equipment.
As our scale up continues to commercial production, we will monitor weekly readouts from each pond providing us with concrete and measurable indications that ZIVO can deliver the quantities and quality at a cost necessary to be profitable for our intended commercial scale and for currently interested third parties. Given the Self Affirmed GRAS (Generally Recognized as Safe) status for our dried whole algal biomass product, we stand well-positioned to work with partners and wholesale buyers with the goal to generate revenue in 2023.
Today’s algae industry is artisanal and fragmented. There is no major source that can deliver to national brands and co-packers consistent quality and quantity of dried algae, and we aim to fill that market need.
In Conclusion
We have implemented a biotech businesses strategy to focus on a product candidate for the treatment of coccidiosis in chickens and focused our agtech business on the achievement of producing our commercial-quality product at scale. We believe this will result in our best opportunity to create value through sustainable revenue in the shortest timeframe possible. We look forward to providing you with updates on potential partnerships, the results of our ongoing studies, and the achievement of commercial milestones as we execute our strategy and build a commercial presence.
In addition to the areas of current focus described above, ZIVO's extensive prior research indicates that there remain numerous additional health benefits or potential disease treatments to be mined from our proprietary algal culture for livestock (in addition to chickens), companion animals, and humans. We intend to pursue these opportunities upon successful completion of the work described in this letter.
On behalf of the ZIVO team, as well as our Board of Directors, I want to thank our shareholders for their continued support. I look forward to keeping you updated as we implement our strategy and emerge as a leader in human and animal health and nutrition.
Sincerely,
John B. Payne
Chairman, President and Chief Executive Officer
September 23, 2022
Would you expect anything less from this company at this point??
Hopefully we won’t have to wait another four months for the next bit of news!
Like you Tony I’m holding my shares as well, but am expecting to be eventually using them as write-offs… I’ve wasted almost 17 years waiting for this company to do something and have given up hope.
Mike,
You mentioned what I think may be a bigger factor than any of us realize…Dahl s screwing the pooch… I wonder if he left such a huge mess in his wake , that even with someone with John Payne’s experience and contacts, may be unable to keep the ZIVO ship from sinking… I also wonder what is happening on the legal front between the company and Dahl… my guess is that the former CEO would love nothing more than to have it appear that the failure of this company fall at the feet of Chris Maggiore and Mr. Payne… of course I have no substantive proof to make a statement like that, but can’t help but wonder… as has been the case for years, nothing makes sense with this company, and does not appear that it will anytime soon.
Mike,
You mentioned what I think may be a bigger factor than any of us realize…Dahl s screwing the pooch… I wonder if he left such a huge mess in his wake , that even with someone with John Payne’s experience and contacts, may be unable to keep the ZIVO ship from sinking… I also wonder what is happening on the legal front between the company and Dahl… my guess is that the former CEO would love nothing more than to have it appear that the failure of this company fall at the feet of Chris Maggiore and Mr. Payne… of course I have no substantive proof to make a statement like that, but can’t help but wonder… as has been the case for years, nothing makes sense with this company, and does not appear that it will anytime soon.
Just saw that as well…What a waste of time and money ZIVO has been.
The odds are 80-1…oh wait I apologize because 80-1 was the worthless reverse split they did close to a year ago
So it’s been 92 days since the announcement was made that John Payne would be taking over as CEO… And we’ve heard absolutely nothing… The reason we’ve heard nothing is because this company is clueless, regardless of who is in charge… The transparency and communication with shareholders promised in that 1/10/2022 press release is just more blah, blah, from a company going nowhere fast… bottom line is, if they had something to say, they would say it… what a sham!!